Robust optimization of the Gross Tumor Volume compared to conventional Planning Target Volume-based planning in photon Stereotactic Body Radiation Therapy of lung tumors
DOI:
https://doi.org/10.2340/1651-226X.2024.40049Keywords:
Stereotactic body radiation therapy, dose planning, isodose volume, organ at risk, tumor motion, plan comparisonAbstract
Background: Robust optimization has been suggested as an approach to reduce the irradiated volume in lung Stereotactic Body Radiation Therapy (SBRT). We performed a retrospective planning study to investigate the potential benefits over Planning Target Volume (PTV)-based planning.
Material and methods: Thirty-nine patients had additional plans using robust optimization with 5-mm isocenter shifts of the Gross Tumor Volume (GTV) created in addition to the PTV-based plan used for treatment. The optimization included the mid-position phase and the extreme breathing phases of the 4D-CT planning scan. The plans were compared for tumor coverage, isodose volumes, and doses to Organs At Risk (OAR). Additionally, we evaluated both plans with respect to observed tumor motion using the peak tumor motion seen on the planning scan and cone-beam CTs.
Results: Statistically significant reductions in irradiated isodose volumes and doses to OAR were achieved with robust optimization, while preserving tumor dose. The reductions were largest for the low-dose volumes and reductions up to 188 ccm was observed. The robust evaluation based on observed peak tumor motion showed comparable target doses between the two planning methods. Accumulated mean GTV-dose was increased by a median of 4.46 Gy and a non-significant increase of 100 Monitor Units (MU) was seen in the robust optimized plans.
Interpretation: The robust plans required more time to prepare, and while it might not be a feasible planning strategy for all lung SBRT patients, we suggest it might be useful for selected patients.
Downloads
References
Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radi-other Oncol. 2017;124(1):11–7.
https://doi.org/10.1016/j.radonc.2017.05.012 DOI: https://doi.org/10.1016/j.radonc.2017.05.012
Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stere-otactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 Suppl 3):S94–100.
https://doi.org/10.1097/JTO.0b013e318074de34 DOI: https://doi.org/10.1097/JTO.0b013e318074de34
Hansen KH, McCullock T, Kunwald S, Kjeldsen R, Pagh A, Mourutzen MT, et al. Klinisk ret-ningslinje: Stereotaktisk strålebehandling af lokal ikke-småcellet lungekræft – version 2.2 DOLG website2022 [Danish national guideline for the delivery of SBRT for localized non-small cell lung cancer] [Internet]. [cited 28-06-2023]. Available from: https://dolg.dk/index.php/stereotaktisk-straalebehandling-ikke-smaacellet-lungekraeft/
Seuntjens J, Lartigau EF, Cora S, Ding GX, Goetsch S, Nuyttens J, et al. ICRU Report 91. Prescribing, recording, and reporting of stereotactic treatments with small photon beams. J Int Comm Radiat Units Meas. 2014;14(2):1–160.
https://doi.org/10.1093/jicru/ndx010 DOI: https://doi.org/10.1093/jicru/ndx010
van Herk M, Remeijer P, Rasch C, Lebesque JV. The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(4):1121–35.
https://doi.org/10.1016/S0360-3016(00)00518-6 DOI: https://doi.org/10.1016/S0360-3016(00)00518-6
de Jong EEC, Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Milder M, et al. Variation in current prescription practice of stereotactic body radiotherapy for pe-ripherally located early stage non-small cell lung cancer: recommendations for prescri-bing and recording according to the ACROP guideline and ICRU report 91. Radiother On-col. 2020;142:217–23.
https://doi.org/10.1016/j.radonc.2019.11.001 DOI: https://doi.org/10.1016/j.radonc.2019.11.001
Korevaar EW, Habraken SJM, Scandurra D, Kierkels RGJ, Unipan M, Eenink MGC, et al. Practical robustness evaluation in radiotherapy – a photon and proton-proof alternative to PTV-based plan evaluation. Radiother Oncol. 2019;141:267–74.
https://doi.org/10.1016/j.radonc.2019.08.005 DOI: https://doi.org/10.1016/j.radonc.2019.08.005
Biston MC, Chiavassa S, Grégoire V, Thariat J, Lacornerie T. Time of PTV is ending, robust optimization comes next. Cancer Radiother. 2020;24(6–7):676–86.
https://doi.org/10.1016/j.canrad.2020.06.016 DOI: https://doi.org/10.1016/j.canrad.2020.06.016
Archibald-Heeren BR, Byrne MV, Hu Y, Cai M, Wang Y. Robust optimization of VMAT for lung cancer: dosimetric implications of motion compensation techniques. J Appl Clin Med Phys. 2017;18(5):104–16.
https://doi.org/10.1002/acm2.12142 DOI: https://doi.org/10.1002/acm2.12142
Zhang X, Rong Y, Morrill S, Fang J, Narayanasamy G, Galhardo E, et al. Robust optimization in lung treatment plans accounting for geometric uncertainty. J Appl Clin Med Phys. 2018;19(3):19–26.
https://doi.org/10.1002/acm2.12291 DOI: https://doi.org/10.1002/acm2.12291
Shang H, Pu Y, Wang Y. Robust optimization of SBRT planning for patients with early stage non-small cell lung cancer. Technol Cancer Res Treat. 2020;19:1533033820916505.
https://doi.org/10.1177/1533033820916505 DOI: https://doi.org/10.1177/1533033820916505
Palazzo G, Mangili P, Deantoni C, Fodor A, Broggi S, Castriconi R, et al. Real-world validat-ion of artificial intelligence-based computed tomography auto-contouring for prostate cancer radiotherapy planning. Phys Imaging Radiat Oncol. 2023;28:100501.
https://doi.org/10.1016/j.phro.2023.100501 DOI: https://doi.org/10.1016/j.phro.2023.100501
Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S70–6.
https://doi.org/10.1016/j.ijrobp.2009.06.091 DOI: https://doi.org/10.1016/j.ijrobp.2009.06.091
Owen D, Siva S, Salama JK, Daly M, Kruser TJ, Giuliani M. Some like it hot: the value of dose and hot spots in lung stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2023;117(1):1–5.
https://doi.org/10.1016/j.ijrobp.2023.03.056 DOI: https://doi.org/10.1016/j.ijrobp.2023.03.056
Moreno AC, Fellman B, Hobbs BP, Liao Z, Gomez DR, Chen A, et al. Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC. J Thorac Oncol. 2020;15(1):101–9.
https://doi.org/10.1016/j.jtho.2019.08.2505 DOI: https://doi.org/10.1016/j.jtho.2019.08.2505
Nielsen TB, Brink C, Jeppesen SS, Schytte T, Hansen O, Nielsen M. Tumour motion analy-sis from planning to end of treatment course for a large cohort of peripheral lung SBRT targets. Acta Oncol. 2021;60(11):1407–12.
https://doi.org/10.1080/0284186X.2021.1949036 DOI: https://doi.org/10.1080/0284186X.2021.1949036
Steiner E, Shieh CC, Caillet V, Booth J, O’Brien R, Briggs A, et al. Both four-dimensional computed tomography and four-dimensional cone beam computed tomography under-predict lung target motion during radiotherapy. Radiother Oncol. 2019;135:65–73.
https://doi.org/10.1016/j.radonc.2019.02.019 DOI: https://doi.org/10.1016/j.radonc.2019.02.019
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Thomas L. Fink, Charlotte Kristiansen, Torben S. Hansen, Torben F. Hansen, Rune S. Thing
This work is licensed under a Creative Commons Attribution 4.0 International License.
